Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances

Cumberland Pharmaceuticals (CPIX) Short-Term Debt issuances (2016 - 2024)

Cumberland Pharmaceuticals' Short-Term Debt issuances history spans 12 years, with the latest figure at $5.5 million for Q4 2024.

On a quarterly basis, Short-Term Debt issuances fell 28.57% to $5.5 million in Q4 2024 year-over-year; TTM through Sep 2025 was $5.5 million, a 86.48% decrease, with the full-year FY2024 number at $38.5 million, up 22.28% from a year prior.
Short-Term Debt issuances hit $5.5 million in Q4 2024 for Cumberland Pharmaceuticals, down from $11.0 million in the prior quarter.
Over the last five years, Short-Term Debt issuances for CPIX hit a ceiling of $20.0 million in Q1 2022 and a floor of $5.5 million in Q4 2024.
Historically, Short-Term Debt issuances has averaged $12.0 million across 5 years, with a median of $11.0 million in 2024.
Biggest five-year swings in Short-Term Debt issuances: soared 88.24% in 2021 and later plummeted 60.0% in 2023.
Tracing CPIX's Short-Term Debt issuances over 5 years: stood at $15.0 million in 2020, then decreased by 6.67% to $14.0 million in 2021, then crashed by 55.71% to $6.2 million in 2022, then grew by 24.19% to $7.7 million in 2023, then fell by 28.57% to $5.5 million in 2024.
Business Quant data shows Short-Term Debt issuances for CPIX at $5.5 million in Q4 2024, $11.0 million in Q3 2024, and $11.0 million in Q2 2024.